Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Profiling involuntarily hospitalized patients according to risk to themselves and/or risk to others].

Fortschritte der Neurologie-Psychiatrie·2026
Same author

New Pharmacological Treatment Approaches for Schizophrenia: Navigating the Post-iclepertin Landscape.

CNS drugs·2026
Same author

Evaluation of a Smartphone App Intervention with Telephone Guidance as Transitional Support from Inpatient Treatment to Continuing Care for Individuals with Alcohol Use Disorder: Results from a Randomized Controlled Trial.

Psychotherapy and psychosomatics·2025
Same author

Correction: Effects of single housing on behavior, corticosterone level and body weight in male and female mice.

Laboratory animal research·2024
Same author

Effects of single housing on behavior, corticosterone level and body weight in male and female mice.

Laboratory animal research·2024
Same author

Serum Metabolites as Potential Markers and Predictors of Depression-like Behavior and Effective Fluoxetine Treatment in Chronically Socially Isolated Rats.

Metabolites·2024

Related Experiment Videos

Bupropion for depression in schizophrenia.

Susanne Englisch1, Dragos Inta, Andrea Eer

  • 1Central Institute of Mental Health, Department of Psychiatry and Psychotherapy, University of Heidelberg, Mannheim, Germany.

Clinical Neuropharmacology
|September 21, 2010
PubMed
Summary

Bupropion, a dual dopamine and norepinephrine reuptake inhibitor, effectively treated major depressive episodes in schizophrenia patients. The antidepressant was generally well-tolerated, showing improvements in negative symptoms and global psychopathology.

Related Experiment Videos

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • The catecholaminergic theory of depression highlights dopamine and norepinephrine dysfunction.
  • Bupropion, a dual reuptake inhibitor, is a potential antidepressant for schizophrenia patients with depressive episodes.
  • Concerns exist regarding bupropion's potential to induce psychosis in patients with a history of psychotic disorders.

Purpose of the Study:

  • To evaluate the antidepressive efficacy, safety, and tolerability of bupropion in patients with schizophrenia and major depressive episodes.
  • To assess the impact of bupropion on positive and negative symptoms, and global psychopathology in this patient population.

Main Methods:

  • A consecutive case series of 5 patients with schizophrenia and major depressive episodes receiving bupropion extended release for 6 weeks.
  • Patients were on stable doses of antipsychotic agents.
  • Standardized psychometric scales including PANSS, SANS, CDSS, HAM-D, and EPS Scale were utilized.

Main Results:

  • Significant improvement in major depressive episodes was observed in all patients.
  • Psychotic positive symptoms remained stable, while negative symptoms and global psychopathology showed considerable improvement.
  • Bupropion was generally well-tolerated, though subtle electroencephalographic deteriorations were noted.

Conclusions:

  • Bupropion appears to be a safe and effective antidepressant for patients with schizophrenia when combined with stable antipsychotic treatment and electroencephalographic monitoring.
  • Further investigation through randomized controlled trials is warranted to confirm these findings.